Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. Issue 11 (November 2013)

• Record Type: Journal Article
• Authors: Dierickx, Daan; Tousseyn, Thomas; Sagaert, Xavier; Fieuws, Steffen; Wlodarska, Iwona; Morscio, Julie; Brepoels, Lieselot; Kuypers, Dirk; Vanhaecke, Johan; Nevens, Frederik; Verleden, Geert; Van Damme-Lombaerts, Rita; Renard, Marleen; Pirenne, Jacques; De Wolf-Peeters, Christiane; Verhoef, Gregor
• Is Part Of: Leukemia & lymphoma. Volume 54:Issue 11(2013:Nov.)
• Page Start: 2433
• Page End: 2440
• Publication Date: 2013-11
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2013.780655
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>Hematopoietic stem cell and solid organ transplant recipients diagnosed with biopsy-confirmed posttransplant lymphoproliferative disorder (PTLD) at our institution from 1989 to 2010 were identified. Patient-, transplant- and disease-related characteristics, prognostic factors and outcome were collected and analyzed. One hundred and forty biopsy-proven cases of PTLD were included. Overall incidence in the transplant population was 2.12%, with heart transplant recipients carrying the highest risk. Most PTLDs were monomorphic (82%), with diffuse large B-cell lymphoma being the most frequent subtype. The majority of cases (70.7%) occurred &gt; 1 year posttransplant, and 66% were Epstein–Barr virus positive. Following initial therapy the overall response rate was 68.5%. Three-year relapse-free and overall survivals were 59% and 49%, respectively. At last follow-up, 44% of the patients were alive. Multivariable analysis identified several classical lymphoma-specific poor prognostic factors for the different outcome measures. The value of the International Prognostic Index was confirmed in our analysis.</p> </abstract>